Figures & data
Figure 1. Emerging strategies for targeting human DCs in situ. Dendritic cell (DC)-based therapeutic vaccines could include antibody-antigen conjugates (left) and nanoparticle-mediated delivery of DC activation (right). Activated DCs subsequently stimulate T cells and potentiate T-cell mediated anticancer immunity.
![Figure 1. Emerging strategies for targeting human DCs in situ. Dendritic cell (DC)-based therapeutic vaccines could include antibody-antigen conjugates (left) and nanoparticle-mediated delivery of DC activation (right). Activated DCs subsequently stimulate T cells and potentiate T-cell mediated anticancer immunity.](/cms/asset/0c862d5d-8a37-410e-ba1a-998faa29a9ce/koni_a_954832_f0001_oc.jpg)